Form 4: Incannex Director Peter Widdows Receives Equity Grant

Incannex Healthcare Inc. Director Peter Widdows was granted 1,686,956 shares of restricted stock under the company's 2023 Equity Incentive Plan.

Summary

• Peter Widdows, a Director of Incannex Healthcare Inc. (IXHL), acquired 1,686,956 shares of common stock on November 14, 2025.
• The acquisition was a grant of restricted stock under the Issuer's 2023 Equity Incentive Plan, with a transaction price of $0 per share.
• Following this transaction, Peter Widdows beneficially owns a total of 1,957,803 shares.
• The granted shares vest in tranches: 421,739 shares on December 10, 2025; 421,739 shares on June 30, 2026; another 421,739 shares on June 30, 2026; and the final 421,739 shares on June 30, 2027.

Sentiment

Score: 7

Explanation: The grant of restricted stock to a director is a positive event as it aligns the director's interests with the long-term performance of the company and shareholder value, indicating commitment and incentivizing growth.

Positives

• The grant of restricted stock aligns the director's long-term interests with those of the shareholders, promoting sustained company performance.
• Equity-based compensation is a standard practice to attract and retain experienced board members.

Future Outlook

The structured vesting schedule for the restricted stock grant indicates a long-term commitment from the director, aligning their future financial incentives with the company's performance over the next several years.

Industry Context

The grant of restricted stock to a director is a common and widely accepted practice in publicly traded companies across various industries. It serves as a key component of executive and director compensation packages, designed to incentivize long-term value creation and align the interests of leadership with those of shareholders.

Comparison to Industry Standards

• The grant of restricted stock to a director is a common practice in publicly traded companies to align executive incentives with shareholder interests.
• While specific benchmarks for Incannex Healthcare Inc. are not provided in this filing, such equity-based compensation is a widely accepted component of executive remuneration across various industries.

Related Party Transactions

• Grant of 1,686,956 shares of restricted stock to Peter Widdows, a Director, under the company's 2023 Equity Incentive Plan.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial incentives with shareholder value creation, potentially leading to more focused long-term strategic decisions.
• Management/Employees: Reinforces the company's commitment to equity-based compensation as a tool for retention and motivation.

Next Steps

• Vesting of 421,739 shares on December 10, 2025.
• Vesting of 843,478 shares on June 30, 2026.
• Vesting of 421,739 shares on June 30, 2027.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a director, which is a standard compensation practice. It does not provide new information that would significantly alter the company's fundamental outlook or warrant a change in investment recommendation based solely on this disclosure.

Keywords

Incannex Healthcare, IXHL, Peter Widdows, Form 4, SEC filing, restricted stock, equity incentive plan, director compensation, stock grant, beneficial ownership